The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: A meta-analysis

Annals of Hepatology

Volumn 14, Issue 2, 2015, Pages 150-160

  Zhang, Xiaoguo ^a   Liu, Lu ^b   Zhang, Meng ^a   Gao, Shuchun ^a   Du, Yizhen ^a   An, Yong ^a   Chen, Shijun ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

ETV; HBV; Review; Severe hepatitis

Indexed keywords

ENTECAVIR; VIRUS DNA; ANTIVIRUS AGENT; GUANINE;

ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INTENSIVE CARE; LACTIC ACIDOSIS; LIVER FAILURE; LIVER FUNCTION; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; NUTRITIONAL SUPPORT; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SENSITIVITY ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; VIRUS REPLICATION; ADULT; ANALOGS AND DERIVATIVES; CHI SQUARE DISTRIBUTION; COMPLICATION; FEMALE; HEPATITIS B, CHRONIC; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SURVIVAL; TIME; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LIVER FAILURE; MALE; MIDDLE AGED; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922664888     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)30776-8     Document Type: Article

References (40)

1. Xie F, Yan L, Lu J, Zheng T, Shi C, Ying J, Shen R, et al. Effects of nucleoside analogue on patients with chronic hepatitis B-associated liver failure: meta-analysis. PLoS One 2013; 8: e54773.
2. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
3. Li LJ. 13th Asia-Pacific congress of clinical microbiology and infection consensus guidelines for diagnosis and treatment of liver failure. Hepatobiliary and Pancreatic Diseases International 2013; 12: 346-54.
4. Association CM. Guidelines for diagnosis and treatment of liver failure. Chin J Clin Infect Dis 2012; 5: 321-7.
5. Gao ZL, Zhang XH. The treatment of complications of liver failure. Zhonghua Gan Zang Bing Za Zhi 2010; 18: 811-13.
6. Mochida S. Indication criteria for liver transplantation for acute liver failure in Japan. Hepatol Res 2008; 38(Suppl. 1): S52-S55.
7. Steadman RH, Van Rensburg A, Kramer DJ. Transplantation for acute liver failure: perioperative management. Curr Opin Organ Transplant 2010; 15: 368-73.
8. Liver EAFTSOT. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
9. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 176-82.
10. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, Chang TT, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 62-72.
11. Chan HL, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, Prabhakar B, et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat 2012; 19: 732-43.
12. Sun LJ, Yu JW, Zhao YH, Kang P, Li SC. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure. J Gastroenterol Hepatol 2010; 25: 583-90.
13. Chen J, Han JH, Liu C, Yu RH, Li FZ, Li QF, Gong GZ. Shortterm entecavir therapy of chronic severe hepatitis B. Hepatobiliary Pancreat Dis Int 2009; 8: 261-6.
14. Cui YL, Yan F, Wang YB, Song XQ, Liu L, Lei XZ, Zheng MH, et al. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure. Dig Dis Sci 2010; 55: 2373-80.
15. Wong VW, Wong GL, Yiu KK, Chim AM, Chu SH, Chan HY, Sung JJ, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 2011; 54: 236-42.
16. Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, Silva JH, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatology International 2009; 3: 269-82.
17. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, Gane E, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatology International 2012; 6: 531-61.
18. Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S, Sarrazin C. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001-06.
19. Association CM. National viral hepatitis control programme. Chin J Hepatol 2000; 8: 324-29.
20. Association CM. Guidelines for chronic hepatitis B (2010). Chinese Hepatology 2011; 16: 2-16.
21. Haimin Y, Yan W, Na J. Baraclude for Treatment of 55 Patients with Chronic Severe Hepatitis B. JPMT 2008; 15: 1100-01.
22. Yuxiang G. Clinical Observation of Entecavir in Treatment of Patients with Chronic Severe Hepatitis B. Chin J Prev Contr Chron Non-commun Dis 2008; 16: 289-90.
23. Biao W. The Effects of Entecavir Treament on the Shortterm Prognosis of the Severe Chronic Hepatitis B. Sun Yat- Sen University 2008.
24. Zhaohui W. Clinical Observation of Entecavir Treatment for Severe Chronic Hepatitis B. Guide of China Medicine 2011; 9: 283-5.
25. Dan L. Prognosis of Entecavir to Treat Severe Chronic Hepatitis B. Health Horizon 2011; 5: 21-2.
26. Lei F. The treatment effect of enticavir on chronic severe hepatitis B. Medical Frontier 2013; 8: 7-8.
27. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000; 32: 734-9.
28. Wang J, Jiang D, Zhang H, Lv S, Rao H, Fei R, Wei L. Proteome responses to stable hepatitis B virus transfection and following interferon alpha treatment in human liver cell line HepG2. Proteomics 2009; 9: 1672-82.
29. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-75.
30. Zhao Z, Han T, Gao Y, Gao Y, Zhang Y, Wu Z. Analysis on the predisposing cause and outcome of 289 cases of hepatitis B patients complicated with chronic or acute liver failure. World J Gastroenterol 2009; 17: 3269-72.
31. Zhang L, Hao CQ, Liu JF, Wang M. Meta-analysis of the short-term effects of lamivudine treatment for severe chronic hepatitis B. Virol J 2013; 10: 134.
32. Tillmann HL, Zachou K, Dalekos GN. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? Liver Int 2012; 32: 544-53.
33. Keating GM. Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease. Drugs 2011; 71: 2511-29.
34. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012; 57: 442-50.
35. Sadler MD, Coffin CS, Lee SS. Entecavir for the treatment of patients with hepatitis B virus-related decompensated cirrhosis. Expert Opin Pharmacother 2013; 14: 1363-9.
36. Ma K, Guo W, Han M, Chen G, Chen T, Wu Z, Yang D, et al. Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure: Establishment of a novel logistical regression model. Hepatology International 2012; 6: 735-43.
37. Chen T, He Y, Liu X, Yan Z, Wang K, Liu H, Zhang S, et al. Nucleoside analogues improve the short-term and longterm prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure. Clin Exp Med 2012; 12: 159-64.
38. Lin B, Pan CQ, Xie D, Xie J, Xie S, Zhang X, Wu B, et al. Entecavir improves the outcome of acute-on-chronic liver failure due to the acute exacerbation of chronic hepatitis B. Hepatology International 2013; 7: 460-7.
39. Lu GF, Tang FA, Zheng PY, Yang PC, Qi YM. Entecavir up-regulates dendritic cell function in patients with chronic hepatitis B. World J Gastroenterol 2008; 14: 1617-21.
40. Yan Y, Mai L, Zheng YB, Zhang SQ, Xu WX, Gao ZL, Ke WM. What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients? World J Gastroenterol 2012; 18: 4604-09.